Estradiol

證據等級: L5

預測適應症: 0 個

Estradiol: Drug Repurposing Evaluation Report

One-Sentence Summary

Estradiol is a naturally occurring oestrogen hormone used broadly in hormone replacement therapy and various oestrogen-deficiency conditions. Currently, no new indications have been predicted by the TxGNN model for this drug, and no clinical trial or literature evidence has been assembled in this evidence pack.

Quick Overview

Item	Content
Original Indication	No approved indication data available
Predicted New Indication	None (no TxGNN prediction generated)
TxGNN Prediction Score	N/A
Evidence Level	L5 (no supporting studies)
Denmark Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Estradiol is the most potent naturally occurring oestrogen and is widely known to act via oestrogen receptors (ERα and ERβ), influencing gene transcription in target tissues including the reproductive system, bone, cardiovascular system, and central nervous system.

However, the TxGNN model has not generated any predicted new indications for estradiol at this time. This may be because estradiol already has a very broad range of approved indications globally (e.g. menopausal symptoms, osteoporosis prevention, hypogonadism, certain breast and prostate cancers), which may limit the novelty of repurposing predictions. Without a specific predicted indication, no mechanism-based rationale can be assessed.

Clinical Trial Evidence

Currently no related clinical trials registered in this evidence pack.

Literature Evidence

Currently no related literature available in this evidence pack.

Denmark Market Information

No marketing authorisations identified for estradiol in the current dataset. Note that estradiol-containing products (e.g. patches, tablets, gels) are widely available in Denmark through centralised EMA authorisations and national authorisations — the absence here likely reflects a data gap rather than true unavailability. Healthcare professionals should consult the Danish Medicines Agency (Lægemiddelstyrelsen) product database or the EMA Community Register for current authorisation status.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Note: Key warnings, contraindications, and drug interaction data were not available in this evidence pack. For estradiol products authorised in the EU, the SmPC is available via the EMA or the Lægemiddelstyrelsen website.

Conclusion and Next Steps

Decision: Hold

Rationale: No new indication has been predicted by the TxGNN model, and no supporting clinical or literature evidence has been assembled. There is currently no actionable repurposing hypothesis to evaluate.

To proceed, the following is needed:

Completion of TxGNN prediction pipeline for estradiol (DB00783) to generate candidate indications
Retrieval of mechanism of action (MOA) data from DrugBank
Collection of Denmark/EU regulatory data (marketing authorisations, SmPC warnings, contraindications)
Assembly of drug-drug interaction (DDI) data
Once a predicted indication is available: systematic collection of clinical trial and literature evidence

This report is for research purposes only and does not constitute medical advice. Any drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.